PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

NCT07428642 · clinicaltrials.gov ↗

COMPLETED

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-Sensitive Prostate Cancer
Prostate Cancer

Interventions

DRUG: Androgen Deprivation Therapy
DRUG: Apalutamide
DRUG: Enzalutamide
DRUG: Darolutamide
DRUG: Rezvilutamide
DRUG: Docetaxel

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]